French pharmaceutical firm Sanofi has signed a Memorandum of Cooperation (MoC) with the Iran Food and Drug Administration, affiliated to the Ministry of Health and Medical Education of Iran, in order to increase its presence in the country.
The MoC is aimed at initiating talks to explore the possibilities where the company may provide its expertise for several projects, which will be studied to further develop existing local manufacturing collaborations and work on programmes to fight chronic and non-communicable diseases.
Go deeper with GlobalData
As part of the deal, the French firm would extend partnerships with local manufacturers to improve the sharing of its expertise in industrial quality standards and increase the transfer of pharmaceutical production technology and know-how.
The company will also collaborate with Iran’s Ministry of Health on programmes to avoid and control several chronic and non-communicable diseases, as well as on managing associated risk factors like diabetes.
It will also evaluate potential collaborations to enhance the availability of exact epidemiological studies and registries.
The company noted that all assessments will be carried out in accordance with applicable laws, including trade restriction rules.
Sanofi board of directors chairman Serge Weinberg said: "With this cooperation, we will consider the possibility to increase our footprint in Iran, where we have been operating for more than ten years, and reinforce our ongoing industrial collaborations."
Both Sanofi and Iran Ministry of Health agree that the collaboration is critical to permit policy makers to create and shape effective and socially impactful policies in the health sector.
The deal will see Sanofi’s provide its extensive knowledge in epidemiological studies and registries on both national and international scales to the Ministry of Health, in order to help policy makers to address the chronic and non-communicable diseases areas such as diabetes, cardiovascular diseases, multiple sclerosis and rare diseases.
